Gene editing: which startup is ahead?

Which gene-editing startups belong in this comparison?

CRISPR Therapeutics, Intellia and Beam form the leading group, while nine smaller companies deserve inclusion because they own distinct editing systems or have already crossed into human testing.

We are comparing 12 independent companies whose main business is building gene-editing medicines for people. That includes public biotechs such as CRISPR Therapeutics, Intellia, Beam, Editas and, since its July 2026 listing, Scribe. They may be listed, but they still behave like startups in the ways that matter here: most products are experimental, losses are funded through capital markets, and one clinical setback can change the company’s future.

The field is deliberately broad. CRISPR Therapeutics and Intellia use conventional CRISPR cutting. Beam uses base editing. Prime uses prime editing. Precision has its own ARCUS nuclease. Tessera is developing Gene Writing. Scribe is starting with epigenetic silencing, which turns a gene down without rewriting its DNA sequence. Caribou uses editing to manufacture donor-derived CAR-T cells. Arbor, Metagenomi and Mammoth are trying to solve delivery and size constraints with newer compact editors.

Vertex is excluded because it is a large pharmaceutical company and CRISPR Therapeutics’ commercialization partner. Verve is excluded because Eli Lilly bought it. We also leave out diagnostics, agricultural editing, research-tool companies, xenotransplantation and cell-therapy companies where gene editing plays only a supporting role.

The funding figures below mainly come from Tracxn and represent reported cumulative funding rounds; Scribe’s figure comes from its SEC filings and excludes its IPO. They show how heavily each company was backed before or around its public listing, but exclude later stock offerings, debt, grants and partnership payments. Current cash is compared separately.

Startup	What it is trying to build	Furthest stage today	Reported cumulative funding
CRISPR Therapeutics	CRISPR medicines across blood, autoimmune, cancer and in vivo liver programs	Approved product	$127M
Intellia Therapeutics	Systemic in vivo CRISPR medicines delivered mainly to the liver	BLA accepted; FDA decision due March 2027	$85M
Beam Therapeutics	Base-edited cell therapies and in vivo medicines	Pivotal AATD cohort dosing; BLA planned	$222M
Precision BioSciences	ARCUS in vivo editing for viral and genetic diseases	Two clinical programs	$136M
Caribou Biosciences	Gene-edited off-the-shelf CAR-T therapies	Phase 1; Phase 3 in start-up	$157M
Prime Medicine	Prime-edited cell and in vivo medicines	Two-patient proof; more trials cleared	$315M
Arbor Biotechnologies	Compact CRISPR editors for rare genetic diseases	Phase 1/2	$304M
Tessera Therapeutics	Gene Writing for correction and insertion	Phase 1/2 started; no data	$610M
Scribe Therapeutics	Compact CRISPR editing and epigenetic silencing	First-in-human study; listed July 2026	About $150M before IPO
Editas Medicine	In vivo gene editing, now led by a cardiovascular program	First trial starting in Australia	$210M
Metagenomi Therapeutics	New editors discovered through metagenomics	IND planned for late 2026	$376M
Mammoth Biosciences	Ultracompact editors for harder-to-reach tissues	Preclinical therapeutic programs	$271M

Is there a clear gene-editing leader today?

CRISPR Therapeutics leads overall, although Intellia is now close enough to threaten that position and Beam has separated from the rest of the field.

The market has one commercial leader, one in vivo challenger under FDA review and one next-generation platform with two serious clinical shots. CRISPR Therapeutics co-developed the only approved medicine in this group. Intellia has completed the first successful randomized Phase 3 trial for a treatment that edits genes inside the body, and its application is now under Priority Review. Beam has human data from both an edited stem-cell therapy and an in vivo base-editing treatment.

The hierarchy is sharp. CRISPR Therapeutics has completed the full journey from laboratory work to approval, reimbursement and rising product revenue. Intellia has cleared the hardest clinical test and the FDA’s filing review. Beam is earlier, but progress across two different products makes it hard to write off as a one-program story. Where gene-editing companies sit against each other is mapped on the market grids in our report on biotech.

Below those three, the market splits into specialists. Precision leads the early hepatitis B race, Caribou has the deepest gene-edited off-the-shelf CAR-T dataset, and Prime has produced the first human proof for prime editing. The remaining companies still need stronger clinical evidence.

Which gene-editing startup has the strongest clinical evidence?

CRISPR Therapeutics has the strongest clinical evidence across the whole market, while Intellia owns the best late-stage evidence for in vivo gene editing.

CASGEVY has cleared regulatory reviews in 39 countries and moved into routine treatment for sickle cell disease and transfusion-dependent beta thalassemia. The FDA has also extended its use to children aged 2 and older, which Vertex says makes about 5,500 more patients potentially eligible. Approval carries more weight than a promising biomarker because regulators have reviewed efficacy, safety, manufacturing and follow-up together.

Intellia’s HAELO study is the strongest evidence produced by a challenger. The randomized trial enrolled 80 people with hereditary angioedema. A single lonvo-z infusion reduced mean monthly attacks by 87% versus placebo. Sixty-two percent of treated patients went through the six-month efficacy period without an attack or continuing preventive therapy, compared with 11% on placebo. The results were published in The New England Journal of Medicine, and Intellia reported no serious adverse events in the lonvo-z arm.

Beam ranks behind those two, though its evidence is broader than most competitors’. Risto-cel has been studied in 31 people with sickle cell disease in the reported dataset, and BEAM-302 had been given to 38 people with alpha-1 antitrypsin deficiency by August 2026. Caribou has treated more patients in its lead program, but cancer response data are awkward to compare because disease severity, previous therapy and follow-up shape the result. Prime’s result is scientifically striking; a two-patient sample cannot carry the same weight.

Safety also separates the field. CASGEVY carries the risks and logistics of stem-cell transplantation and busulfan conditioning. Lonvo-z has the cleanest randomized in vivo safety package so far, though the serious liver event in Intellia’s separate nex-z program means the wider platform is not fully de-risked.

Startup	Strongest human evidence	Approximate scale	Our reading
CRISPR Therapeutics	Approved CASGEVY, authorized in 39 countries and in commercial use	Hundreds in the treatment journey	Deepest total validation
Intellia	Positive randomized HAELO Phase 3 trial, published in NEJM	80 randomized patients	Best in vivo evidence
Beam	Human proof in sickle cell disease and AATD	31 risto-cel patients; 38 dosed with BEAM-302	Broadest next-generation proof
Caribou	Long-term lymphoma responses with vispa-cel	85 treated in the wider program	Strong specialist dataset with difficult safety questions
Precision	Direct liver-biopsy evidence against HBV cccDNA	16 patients, 38 administrations	Small study with unusually meaningful biology
Prime	Large correction in p47phox CGD	Two patients	Breakthrough proof, far too small for certainty

When will the FDA decide on Intellia’s lonvo-z?

The FDA has set March 10, 2027 as its target date for lonvo-z, which makes Intellia the clear favorite to win the next important gene-editing approval.

In September 2026, the FDA accepted Intellia’s biologics license application for lonvo-z in hereditary angioedema and granted it Priority Review. Both Intellia and HCPLive reported that the agency does not currently plan an advisory committee meeting. Intellia says it plans a US launch in the first half of 2027 if the drug is approved. If that happens, lonvo-z would be the first approved CRISPR therapy that edits genes directly inside the body.

The bar is real. Patients with hereditary angioedema already have effective preventive drugs, so lonvo-z must win on convenience and durability, not only on efficacy. An on-time approval would still be a turning point for the whole field, because it would show regulators accepting a permanent in vivo edit in a non-fatal disease.

Beam is the closest follower. It says it could submit risto-cel for sickle cell disease as early as the end of 2026. Its BEAM-302 pivotal cohort of about 50 patients is designed for a possible accelerated approval, but Beam itself notes that FDA agreement to that path is not guaranteed.

Prime is a more distant outsider. It says it is working toward a filing for PM359 in the first half of 2027, but that plan rests on two treated patients so far.

Which gene-editing startup has built a real business?

CRISPR Therapeutics is the only company in this comparison with a real product business, and that business is now growing quickly.

Vertex reported $76.4 million of CASGEVY revenue in the second quarter of 2026, up 78% from the first quarter and 151% from a year earlier. Germany secured reimbursement for patients aged 12 and older in May 2026, and filings for younger children are under review in the UK and Saudi Arabia. Vertex does not give a separate CASGEVY sales forecast; it guides to $500 million or more of 2026 revenue from CASGEVY and its pain drug JOURNAVX combined.

The Vertex partnership deserves much of the credit. Vertex leads global development, manufacturing and commercialization, while CRISPR Therapeutics receives 40% of program profits and pays 40% of costs. The arrangement limits CRISPR Therapeutics’ share of the economics, but it gave CASGEVY a global commercial operation that a young biotech would have struggled to build alone.

Other companies report revenue from licensing, collaborations or milestone payments. Those agreements can validate the technology and finance development, but they do not show that doctors are prescribing a product or that patients are creating repeatable demand. Milestone payments and product sales are different business models, and we compare which ones make money in our market report about biotech.

Is Intellia the leader in in vivo gene editing now?

Intellia leads in vivo gene editing because lonvo-z has moved direct editing inside the body from early promise to Phase 3 evidence and an accepted application.

Lonvo-z is designed to switch off the KLKB1 gene in liver cells after one infusion and lower the protein behind hereditary-angioedema attacks. The result is convincing because patients already have effective preventive drugs. Intellia had to show enough efficacy and convenience to compete with treatments that already control the disease.

The detailed HAELO results strengthen that case. Beyond the 87% overall reduction in attacks, Intellia reported an 89% drop in attacks requiring on-demand treatment and a 91% reduction in moderate or severe attacks. As of the February 2026 data cutoff, treated patients remained free of long-term preventive therapy.

CRISPR Therapeutics is the main in vivo rival to watch. In August 2026, one-year CTX310 data published in NEJM showed a mean 52.5% drop in LDL cholesterol and a 47.8% drop in triglycerides at the highest dose, but only four patients received that dose. Beam’s BEAM-302 is the closest next-generation competitor. Precision has shown that ARCUS can reach hepatitis B DNA inside the liver, but its study is still small.

The nex-z liver-safety episode still hangs over Intellia’s broader platform. Intellia said a genomic analysis linked the largest liver-enzyme rises to one specific HLA gene variant, and it is sharing genotyping results with investigators in its Phase 3 trials. No rival has matched lonvo-z’s late-stage combination of efficacy, tolerability and regulatory progress.

Can Beam catch Intellia now that its BEAM-302 pivotal cohort is dosing?

Beam has the strongest next-generation platform today, but it will not catch Intellia before 2027, because neither of its lead programs has reached an FDA filing yet.

Risto-cel edits a patient’s blood-forming stem cells outside the body. In the reported 31-patient dataset, fetal hemoglobin rose above 60% on average, sickle hemoglobin fell below 40%, and severe vaso-occlusive crises stopped after engraftment during the available follow-up. Dosing is now complete in the BEACON trial, and Beam expects updated data and a possible filing as early as the end of 2026.

BEAM-302 tests a harder proposition: correcting a disease-causing mutation directly inside the liver. In data presented at the European Respiratory Society congress in September 2026, mean total alpha-1 antitrypsin at the 60-milligram dose reached 14.4 micromolar in one patient group and 13.5 micromolar in another, above the 11-micromolar level commonly treated as protective. Corrected M-AAT made up 93% of circulating protein, and harmful Z-AAT fell by 84%. One patient had a transient grade 3 liver-enzyme rise that resolved without treatment.

Together, the programs show that Beam’s editing system works in manufactured stem cells and through systemic liver delivery. That makes the platform more credible than a pipeline supported by one asset or one tissue. The FDA also cleared BEAM-304 for phenylketonuria in June 2026.

Beam ended June 2026 with $1.15 billion and expects its runway, including a $200 million debt draw it plans to make, to reach mid-2029. It remains third because it has no approved product or completed Phase 3 trial.

Is Precision BioSciences the most underrated gene-editing company?

Precision BioSciences is the most underrated clinical challenger because its hepatitis B program has produced direct evidence against the viral reservoir that keeps the infection alive.

Current hepatitis B drugs can suppress viral replication, but they usually leave covalently closed circular DNA, known as cccDNA, inside liver cells. Precision’s PBGENE-HBV is designed to attack that reservoir. In liver-biopsy data presented at the European liver congress in May 2026, one patient showed a tenfold reduction in cccDNA-derived transcripts after two doses, and a second patient showed a cumulative effect after three doses. In the blood, pregenomic RNA became undetectable in every patient who had detectable levels before treatment, and surface antigen fell in all treated patients.

The sample is small: 16 people had received 38 administrations across five cohorts. The data need longer follow-up, more biopsies and a demonstrated link to durable functional cure. Even with those limits, the result is more informative than a generic fall in a downstream blood marker. Small studies with early biopsy evidence are why we separate what works in gene editing from what is still being tested in our report covering the biotech market.

Repeat dosing adds another useful piece of evidence. Many gene-editing programs are built around one administration because immune reactions or delivery toxicity may complicate a second dose. Precision reported no dose-limiting toxicities across its 38 administrations, and the next hepatitis B data are due by the end of 2026.

The company is also recruiting boys aged 2 to 7 for PBGENE-DMD in Duchenne muscular dystrophy, with first safety data expected by year-end. Its $112 million of cash is far below the top three, but its clinical evidence is strong enough to justify fourth place.

Can Caribou’s gene-edited CAR-T work at commercial scale?

Caribou has built the strongest gene-edited off-the-shelf CAR-T program, but vispa-cel carries enough safety and financing risk to keep the company outside the top four.

Vispa-cel uses donor cells that can be produced in batches and stored, avoiding the patient-by-patient manufacturing delay of conventional CAR-T. In the 27-patient subgroup that best matches Caribou’s planned Phase 3 treatment, the overall response rate was 82%, the complete-response rate was 67%, and median progression-free survival reached 17.1 months.

The safety record is harder. The same subgroup had one treatment-related death from an immune-effector-cell-associated inflammatory syndrome and one death considered possibly related because of progressive multifocal leukoencephalopathy. Severe infections and prolonged low blood-cell counts also occurred.

Caribou has agreed with the FDA on a roughly 250-patient randomized Phase 3 trial, called ANTLER-3, but it has not announced a start date. The company ended June 2026 with $113.8 million, enough to reach the end of 2027 and cover only some start-up work. In August 2026, it said it was exploring options to fund the full trial.

Its second program adds some weight. CB-011 produced a 92% response rate in 12 multiple myeloma patients who had not received BCMA therapy before. Vispa-cel could move Caribou sharply upward if Phase 3 is fully financed and confirms durable responses with acceptable safety.

Can Prime Medicine file for approval on two patients and limited cash?

Prime Medicine has proved that prime editing can create a large correction in humans, but its plan to file on two patients and its short runway make it a high-risk sixth.

PM359 corrects a mutation in blood-forming stem cells from people with a rare form of chronic granulomatous disease. The first two treated patients reached 69% and 83% DHR-positive neutrophils by day 30, more than three times the 20% reference level for expected benefit. The FDA granted RMAT designation in June 2026, and Prime says it is working toward a BLA submission in the first half of 2027.

Two successful patients cannot show how often manufacturing fails, whether editing varies widely, or whether rare safety problems emerge. The therapy also uses stem-cell collection and conditioning, so it says little about Prime’s in vivo liver programs.

Those programs are moving. Regulators in New Zealand and the US cleared the Wilson disease study in June and July 2026, with first data expected in 2027. In July 2026, an arbitration tribunal ruled that Prime’s AATD program falls within its own field and rejected Beam’s breach claim.

Money is the constraint. Prime reported $108.8 million at the end of June 2026 and said that cash funds operations only into 2027. We rank it sixth because the first result is exceptional but narrow, and a new financing or partnership looks necessary.

Which gene-editing startup has the strongest and hardest-to-copy platform?

CRISPR Therapeutics has the broadest mature pipeline, while Beam has the strongest scientific platform that competitors would struggle to copy.

CRISPR Therapeutics spans an approved blood-disorder product, allogeneic cell therapy for autoimmune disease and cancer, cardiovascular editing, liver-directed correction and regenerative medicine. In 2026, it started Phase 1 trials for CTX340 in hypertension and CTX460 in alpha-1 antitrypsin deficiency. Some programs use siRNA or cell replacement alongside gene editing, so the company is broader than a pure editor. Even after that discount, it has more clinically advanced ways to create value than any rival.

Beam’s pipeline is smaller but more internally consistent. Risto-cel, BEAM-302, BEAM-301 and BEAM-304 all rely on the company’s base-editing and delivery systems. Copying one base-editing enzyme would not reproduce the full system. A rival would need to match guide design, control unwanted edits, reach the correct cells, manufacture the treatment consistently and reproduce the clinical results.

Intellia has built the deepest operating knowledge in systemic in vivo CRISPR. It has taken a treatment from first human dosing through randomized Phase 3 and an accepted application, handled a serious safety interruption in another program and worked with regulators to restart development. That experience cannot be licensed overnight.

CRISPR Therapeutics has the strongest commercial moat. Through CASGEVY and Vertex, it has learned how to qualify treatment centers, release patient-specific products, secure reimbursement and operate across several regulatory systems.

Prime and Tessera can describe a wider theoretical editing range, while Scribe, Mammoth, Arbor and Metagenomi may eventually reach tissues or targets that larger CRISPR systems cannot. Those advantages remain mostly unproven in people.

Beam gets the scientific-platform lead because its differentiation has already produced results in two human settings. CRISPR Therapeutics still owns the broader and more valuable position today. Platforms that rivals cannot easily copy are part of what leaders consistently do differently, which we study in our biotech market report.

Which gene-editing startup has the most financial firepower?

CRISPR Therapeutics has the strongest balance sheet by a wide margin, with about twice Beam’s cash and almost four times Intellia’s.

CRISPR Therapeutics ended June 2026 with $2.36 billion, helped by $585 million of net proceeds from convertible notes issued in March. Beam had $1.15 billion and expects its runway to reach mid-2029. Intellia had $628 million after an April 2026 stock sale that raised about $195 million net, and says that funds operations at least into 2028, before any lonvo-z sales.

The gap matters because late-stage gene editing is expensive. Beam can prepare a sickle-cell filing and run a pivotal AATD cohort without choosing between them. Intellia can finance a lonvo-z launch and its nex-z Phase 3 trials. CRISPR Therapeutics can absorb setbacks across several programs.

Smaller competitors have less room for error. At the end of June 2026, Editas had about $212 million, Metagenomi $121 million, Caribou $114 million, Precision $112 million and Prime $109 million. Scribe raised about $129 million in its July IPO, plus $7.5 million from Sanofi, but has not yet reported a post-IPO cash balance. Prime’s runway reaches only into 2027, and Metagenomi’s and Caribou’s end in late 2027.

Funding cannot rescue a weak product, but a thin balance sheet can stop a promising program before its decisive trial.

Startup	Latest reported cash	Relative to CRISPR Therapeutics	Practical implication
CRISPR Therapeutics	$2.36B	100%	Can fund several major programs and absorb setbacks
Beam Therapeutics	$1.15B	49%	Can pursue two late-stage paths together
Intellia Therapeutics	$628M	27%	Enough for launch and Phase 3 work into 2028
Editas Medicine	$212M	9%	Runway into the second half of 2028 for EDIT-401 to reach humans
Metagenomi Therapeutics	$121M	5%	Reaches first clinical entry, with runway through late 2027
Caribou Biosciences	$114M	5%	Does not fully cover the planned pivotal program
Precision BioSciences	$112M	5%	Human progress is strong relative to capital, but risk remains high
Prime Medicine	$109M	5%	Runway only into 2027; needs a partner or new money

Which gene-editing startup has the strongest momentum right now?

Intellia has the strongest momentum today, Beam is moving almost as quickly across more programs, and Scribe has become the most interesting early-stage mover.

Intellia’s year has been decisive. It reported a successful Phase 3 trial, published it in NEJM, raised fresh capital in April, and in September 2026 won FDA acceptance and Priority Review for lonvo-z. Enrollment in its nex-z Phase 3 nerve-disease trial is expected to finish in the second half of 2026.

Beam’s progress is broader. It finished dosing in its sickle-cell trial, started its pivotal BEAM-302 cohort in July 2026, presented durable AATD data with up to 18 months of follow-up in September, and received FDA clearance for BEAM-304.

CRISPR Therapeutics is moving too. CASGEVY sales rose 78% from one quarter to the next, and its CTX310 cholesterol data reached NEJM in August 2026. Prime won its arbitration against Beam and cleared its Wilson disease study. Precision added more hepatitis B biopsy evidence. Tessera has started its first clinical study, and Regeneron agreed in December 2025 to co-fund TSRA-196.

Scribe deserves attention. It priced an upsized IPO at $15 a share in July 2026, and the stock closed 44% higher on its first day, according to IPOScoop. STX-1150 aims to lower LDL cholesterol for years by silencing PCSK9 without changing the DNA sequence, with first human data expected in the first half of 2027.

Intellia still has the sharpest change in competitive position, because no other company in this group has a drug under FDA review.

Which gene-editing startups are actually ahead?

CRISPR Therapeutics leads overall, Intellia is the only company close enough to take first place soon, and Beam is the strongest long-term platform challenger.

We weight approval, repeatable clinical evidence and commercial execution most heavily. Platform elegance, funding and partnerships matter, but they cannot compensate indefinitely for missing clinical proof.

CRISPR Therapeutics has completed the whole cycle once. CASGEVY is approved in 39 countries, reimbursed, and generated $76.4 million in the second quarter of 2026. The company also has the largest balance sheet and a growing in vivo pipeline. Vertex receives 60% of the economics and runs commercialization, but CRISPR Therapeutics still owns the strongest body of proof.

Intellia sits much closer than a usual second-place biotech. Lonvo-z has positive randomized Phase 3 data, an application under Priority Review with a March 10, 2027 target date, and a design that should scale more easily than a stem-cell therapy. Intellia can take first place if lonvo-z wins approval, launches cleanly and shows durable real-world benefit.

Beam holds third without much debate. Two human programs support the base-editing platform, its pivotal AATD cohort is dosing, and it has the cash to pursue both late-stage paths. A risto-cel filing and clean pivotal BEAM-302 data would move Beam closer to the top two.

Precision ranks fourth because its human HBV result is unusually specific and a second in vivo program is recruiting. Caribou ranks fifth because vispa-cel has meaningful scale and a Phase 3 design, though safety and financing remain heavy constraints. Prime ranks sixth because the first human prime-editing result is exceptional but rests on two patients and a short runway.

The lower half remains fluid. Arbor is testing its editor in people. Scribe is in the clinic and newly listed. Tessera has started its first trial but has no disclosed patient results. Editas has the cash to reach humans with EDIT-401. Metagenomi and Mammoth still need human therapeutic evidence.

CRISPR Therapeutics leads the market that exists today. Intellia leads the race to commercial in vivo editing. Beam has the best chance to own the next generation of the technology. Rankings like this shift at specific milestones, which is why we track market signals every quarter in our report on biotech.

Rank	Startup	Why it ranks here	What could change the ranking
1	CRISPR Therapeutics	Only company here with an approved, reimbursed and revenue-producing gene-editing medicine; deepest commercial proof and strongest balance sheet	Slow CASGEVY growth or weak follow-on programs could let Intellia pass it
2	Intellia Therapeutics	Successful randomized Phase 3 in vivo trial, BLA under Priority Review and the easiest leading product to scale	Approval by March 2027 and a clean launch could move Intellia to first; a delay or safety issue could push it back
3	Beam Therapeutics	Best validated next-generation platform, two important human datasets, a dosing pivotal cohort and ample capital	Risto-cel submission plus positive BEAM-302 pivotal data could create a top-two company
4	Precision BioSciences	Direct human evidence against HBV cccDNA and two clinical in vivo programs	Durable functional-cure evidence in hepatitis B would move Precision sharply higher
5	Caribou Biosciences	Strongest gene-edited off-the-shelf CAR-T dataset and an FDA-aligned Phase 3 design	Full financing and safer durable Phase 3 results would support a higher rank
6	Prime Medicine	First convincing human prime-editing result and a very broad technical ceiling	More patients, in vivo liver data and new funding are needed
7	Arbor Biotechnologies	Already dosing a compact in vivo editor, with regulatory designations and Chiesi support	Convincing pharmacodynamic or efficacy data could move Arbor into the upper group
8	Scribe Therapeutics	First-in-human study underway, a differentiated reversible-silencing approach and fresh IPO capital	Human LDL reduction with a clean safety profile, expected in 2027, would change the ranking quickly
9	Tessera Therapeutics	Ambitious Gene Writing platform, a started AATD study and Regeneron as co-funder	The first treated-patient data will decide whether the platform can move beyond promise
10	Editas Medicine	Valuable editing know-how, cash into the second half of 2028 and a rebuilt cardiovascular program	EDIT-401 needs to enter humans and reproduce its preclinical effect, with first data due in 2027
11	Metagenomi Therapeutics	Broad editor-discovery engine and a hemophilia program with an IND planned for late 2026	Human factor VIII production would give the company its first decisive proof
12	Mammoth Biosciences	Ultracompact editors could unlock difficult tissues, with major pharmaceutical validation	A therapeutic program must enter humans before Mammoth can rank with clinical-stage rivals